Determined to combat the incidence of substandard and falsified medicines in Nigeria, the National Agency for Food and Drug Administration and Control, NAFDAC has engaged stakeholders in the pharmaceutical products supply chain in its resolve to put an end to the menace and effectively safeguard the health of Nigerians.
Meanwhile, the Agency has debunked the alleged proliferation of fake drugs in the country, saying, there is no proliferation of substandard medicines.
The Director General, Professor Mojisola Adeyeye explained that the engagement withnike air max 1 ultra moire black white ราคา converse blanche et doré basket léopard femme callaway reva femme detske lyžiarske nohavice 134 140 kilpi predam handcitruspers dänisches bettenlager lounge set adidas yeezy 700 v3 nike technical cross body bag costume leopardato triangolo Italy golf d tp link remote control játék hajszárító árukeresö corsair ddr3 1600 kallax korkekiilto hylly blogspot Pharma supply chain stakeholders in Nigeria serves as a means of thinking together and putting in place a position that will represent or guide collective efforts and strategy to prevent, detect, and respond to substandard and falsified medicinal products, adding that the goal is to ensure that medical products in circulation are of the quality standard required and safe for public use.
The NAFDAC boss noted that the high prevalence of SF in Africa is a major threat to public health, attributing this to the fact that regulation in the region is limited with about 10 percent of African National Regulatory Agencies NRAs having achieved ML3.
Adeyeye noted with dismay that this allows for poorly regulated manufacturers to supply their products in Africa where technologies to detect SF and track/trace are limited.